Nav: Home

An itch to scratch: NCATS, NIDCR scientists identify potential approach to chronic problem

July 12, 2019

Chronic itch goes beyond being just a simple annoyance; it can greatly affect a person's quality of life. While scientists have some clues to its causes, effective therapies have been elusive.

Now, using a technique called quantitative high-throughput screening to sort through more than 86,000 compounds at the same time, researchers at NCATS and the National Institute of Dental and Craniofacial Research (NIDCR) report a new strategy that may eventually help alleviate chronic itch. They've shown that blocking a receptor, or docking station, found on the surface of both mouse and human spinal cord neurons could be key.

Several years ago, Mark Hoon, Ph.D., and his colleagues at NIDCR found a receptor, Npr1, on mouse spinal cord neurons for a protein associated with itch. The protein fit into Npr1 like a key into a lock, helping turn on the itch sensation. Npr1 appeared to be a potential target for drugs to halt itch.

Hoon contacted NCATS scientist James Inglese, Ph.D., and his team for help in identifying compounds that could block Npr1 activity. The researchers developed a series of assays, or tests, and used robots to screen compounds in human cells, finding approximately 1,400 molecules worth examining more closely. They then developed additional assays to narrow the list to 15 compounds. They showed a subset of these compounds could halt both human and mouse versions of the receptor from working. A follow-up study in mice showed that blocking the receptor reduced scratching.

Next, the scientists will examine more candidate compounds and determine how they block Npr1. They hope the findings will help them choose which compounds to study further and chemically modify as potential anti-itch drugs. Hoon, Inglese and their colleagues reported the results online July 10 in Science Translational Medicine.

"This is a proof-of-concept study and an important application of what NCATS does," Inglese said. "We wanted to show that by pharmacologically blocking the target receptor, the approach could be successful in finding a drug to treat chronic itch. Because it can take a long time to develop an ideal compound, the rationale behind the approach needs to be well vetted."
-end-


NIH/National Center for Advancing Translational Sciences (NCATS)

Related Chronic Itch Articles:

Scratching the surface of how your brain senses an itch
Light touch plays a critical role in everyday tasks, such as picking up a glass or playing a musical instrument, as well as for detecting the touch of, say, biting insects.
An itch to scratch: NCATS, NIDCR scientists identify potential approach to chronic problem
While scientists have some clues to the causes of troubling chronic itch, effective therapies have been elusive.
Seeking better detection for chronic malaria
In people with chronic malaria, certain metabolic systems in the blood change to support a long-term host-parasite relationship, a finding that is key to eventually developing better detection, treatment and eradication of the disease, according to research published today in the Journal of Clinical Investigation Insight.
Chronic kidney disease: Everyone's concern
850 million people worldwide are affected by kidney disease. This worrying figure was published last June.
Using light to stop itch
Itch is easily one of the most annoying sensations. For chronic skin diseases like eczema, it's a major symptom.
More Chronic Itch News and Chronic Itch Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...